Karakteristik Klinik dan Pola Antibiotik pada Pasien Rawat Inap Coronavirus Disease 2019 di Rumah Sakit Wava Husada Malang
Abstract
Coronavirus Disease 2019 (COVID-19) disebabkan oleh infeksi virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) yang mengakibatkan manifestasi klinik pneumonia. Pneumonia pada COVID-19 utamanya disebabkan virus, namun bakteri dapat berperan sebagai penyebab ko-infeksi sehingga meningkatkan risiko kematian. Studi serial kasus ini menyajikan karakteristik klinik dan gambaran regimen antibiotik yang diberikan pada pasien COVID-19 di Rumah Sakit Wava Husada Malang dengan menggunakan data rekam medik. Sebanyak 21 pasien yang terpilih selama periode bulan Maret–Agustus 2020 menunjukkan tingkat keparahan sedang-berat yang selanjutnya dilakukan analisis secara deskriptif. Rata-rata usia pasien yaitu 52±13 tahun dan sebanyak 62% adalah pria. Gejala yang paling banyak ditemukan yaitu sesak (81%) dan batuk (76,2%). Selain itu, beberapa gejala lain yang ditemukan antara lain demam (57,1%), diare (19%), mual/muntah (33,3%), pusing (14,3%) dan anoreksia (4,8%). Seluruh pasien memiliki gambaran radiologi pneumonia dengan sebagian besar menunjukkan jumlah leukosit normal dan jumlah limfosit yang rendah. Sebesar 76,2% (16 pasien) mendapatkan antibiotik tunggal dan 23,8% (5 pasien) mendapatkan kombinasi. Levofloksasin merupakan antibiotik yang paling sering diberikan baik dalam bentuk tunggal maupun kombinasi dengan nilai tengah durasi pemberian antibiotik yaitu 11 hari. Lama rawat inap pasien yaitu antara 12–24 hari dengan kondisi membaik sebesar 71,4% sementara 28,6% meninggal. Pengukuran prokalsitonin perlu diupayakan di rumah sakit tempat pengambilan data sebagai strategi penatalayanan penggunaan antibiotik pada pasien COVID-19.
Kata kunci: Antibiotik, COVID-19, karakteristik klinik, ko-infeksi bakteri
Clinical Characteristic and Antibiotic Patterns among Coronavirus Disease 2019 In-patient Wava Husada Hospital Malang
Abstract
Coronavirus Disease 2019 (COVID-19) is an infection caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which resulted in the clinical manifestation of pneumonia. A virus mainly causes pneumonia COVID-19, but bacterial co-infection plays a role in increasing mortality. This case series aimed to identify clinical characteristics and antibiotic use in treating COVID-19 patients at Wava Husada Hospital Malang. Data of a total sample of 21 patients selected from March to August 2020 showed moderate to severe infection and was further analyzed descriptively. The mean age of patients was 52±13 years, and 62% were men. Meanwhile, the most common symptoms were shortness of breath and cough with 81% and 76.2%, respectively. Several symptoms found include fever, diarrhea, nausea/vomiting, dizziness, and anorexia at 57.1%, 19%, 33.3%, 14.3%, and 4.8%. The patients had radiological features of pneumonia, where most of them had normal leukocyte and low lymphocyte counts. Additionally, 76.2% or 16 patients received antibiotic monotherapy, and 23.8% or 5 patients received the combination. Levofloxacin is the most commonly administered antibiotics, either single or combined, with a median duration of 11 days. Patients' length of stay ranged from 12 to 24 days; where 71.4% were discharged home, and 28.6% died. Procalcitonin measurement should be attempted as a stewardship strategy for using antibiotics in COVID-19 patients.
Keywords: Antibiotic, bacterial co-infection, clinical characteristics, COVID-19
Keywords
Full Text:
PDF (Bahasa Indonesia)References
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2021 [Diakses pada: 23 Februari 2021]. Tersedia dari: https://covid19.who.int
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus (COVID-19) outbreak. J Autoimmun. 2020;109(February):102433. doi: 10.1016/j.jaut.2020.102433
Satgas COVID-19 Malang Raya. Laporan PPKM Malang Raya 27 Januari 2021. 2021 [Diakses pada: 23 Februari 2021]. Tersedia dari: http://satgascovid19.malangkab.go.id/ppkm.html
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323(11):1061–9. doi: 10.1001/jama.2020.1585
Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA score. Front Microbiol. 2019;10(12):2752. doi: 10.3389/fmicb.2019.02752
Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: Don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808–10. doi: 10.1016/j.cmi.2020.04.024
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Protokol tatalaksana COVID-19. Edisi 1. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI); 2020.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi: 10.1056/NEJMoa2002032
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395 (10223):507–13. doi: 10.1016/S0140-6736(20)30211-7
Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, et al. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: A descriptive study. BMC Infect Dis. 2020;20:519. doi: 10.1186/s12879-020-05242-w
Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 novel coronavirus (2019-NCoV) pneumonia. Radiology. 2020;295(1):210–7. doi: 10.1148/radiol.2020200274
Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459–68. doi: 10.1093/cid/ciaa530
Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–70.
Bengoechea JA, Bamford CG. SARS-CoV-2, bacterial co-infections, and AMR: The deadly trio in COVID-19? EMBO Mol Med. 2020;12(7):e12560. doi: 10.15252/emmm.202012560
Beović B, Doušak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: A “snapshot” Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386–90. doi: 10.1093/jac/dkaa326
World Health Organization. Clinical management of COVID-19 interim guidance 27 May 2020. 2020 [Diakses pada: 20 September 2020]. Tersedia dari: https://apps.who.int/iris/handle/10665/33 2196
Liu S, Tong X, Ma Y, Wang D, Huang J, Zhang L, et al. Respiratory fluoroquinolones monotherapy vs. β -lactams with or without macrolides for hospitalized community-acquired pneumonia patients: A meta-analysis. Front Pharmacol. 2019;10:489. doi: 10.3389/fphar.2019.00489
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. doi: 10.1001/jamainternmed.2020.0994
Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):13093. doi: 10.1038/s41598-020-70143-6
Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Macho O, López GF, et al. Observational study of azithromycin in hospitalized patients with COVID-19. PLoS One. 2020;15(9):e0238681. doi: 10.1371/journal.pone.0238681
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): A randomised clinical trial. Lancet. 2020;396(10256):959–67. doi: 10.1016/S0140-6736(20)31862-6
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67. doi: 10.1164/rccm.201908-1581ST
DOI: https://doi.org/10.15416/ijcp.2021.10.4.321
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by